PETQ PetIQ Inc. Class A

PetIQ, Inc. Announces Business Update Related to COVID-19

PetIQ, Inc. Announces Business Update Related to COVID-19

EAGLE, Idaho, March 20, 2020 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced that out of an abundance of caution for its employees and customers in response to COVID-19 all veterinary community clinics and wellness centers will temporarily close effective Friday, March 20, 2020. The Company is continuously monitoring this situation and will reopen its veterinary service locations as soon as practical.  PetIQ’s veterinarian products business continues to perform well with full availability of its pet health and wellness items at its retail and e-commerce partners.

“The coronavirus has created an unprecedented situation that requires PetIQ to take action,” commented Cord Christensen, PetIQ’s Chairman and Chief Executive Officer. “We are prioritizing the health and safety of our veterinarians, associates, customers, and retail partners by temporarily closing our veterinary community clinics and wellness centers to reduce the risk of spreading the virus further.  For the immediate future, those employees displaced during this time will be paid to help them support their needs.  PetIQ is fortunate that its 100% USA-based manufacturing and distribution centers supporting its veterinarian products business are performing in-line with our budgeted forecasts.  Pet parents can provide their pets with preventive wellness with access to our over 2,000 health and wellness items through our retail and e-commerce partners, although near-term they will experience a gap in our veterinary wellness services.”

The Company has also proactively drawn against its Revolving Credit Facility as a precautionary measure to provide financial flexibility given the uncertainties in the marketplace as a result of COVID-19.  With this draw the Company has liquidity in excess of $50 million with no meaningful maturities due until July of 2024. 

About PetIQ

PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services.  The company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded distributed medications, which is further supported by its own world-class medications manufacturing facility in Omaha, Nebraska.  The company’s national service platform, VIP Petcare, operates in over 3,400 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services.  PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could" and similar expressions.  Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the impact of COVID-19 on our business, our ability to successfully grow our business through acquisitions; our dependency on a limited number of customers; our ability to implement our growth strategy effectively; disruptions in our manufacturing and distribution chains; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to manage our manufacturing and supply chain effectively; disruptions in our manufacturing and distribution chains; our ability to introduce new products and improve existing products; our failure to protect our intellectual property; costs associated with governmental regulation; our ability to keep and retain key employees; our ability to sustain profitability; and the risks set forth under the “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed time to time with the Securities and Exchange Commission.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.  The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.

Investor Relations Contact:

ICR

Jeff Sonnek

646-277-1263



Media Relations Contact: 

ICR

Cory Ziskind

646-277-1232



EN
20/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PetIQ Inc. Class A

 PRESS RELEASE

PetIQ Names Camillo Pane as Chief Executive Officer

PetIQ Names Camillo Pane as Chief Executive Officer Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane’s passion for making a difference in the lives of consumers has been a constant focus through...

 PRESS RELEASE

PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Gr...

PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the tran...

 PRESS RELEASE

PetIQ, Inc. Announces Results of Special Meeting of Stockholders

PetIQ, Inc. Announces Results of Special Meeting of Stockholders Reports Merger Agreement with Bansk Group Approved by Stockholders and Anticipates a Closing Date of October 25, 2024 EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the “Agreement”) pursuant to which Bansk Group will acquir...

 PRESS RELEASE

PetIQ, Inc. Reports Second Quarter 2024 Financial Results

PetIQ, Inc. Reports Second Quarter 2024 Financial Results Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ’s Founder and CEO, commented, “We are ...

 PRESS RELEASE

PetIQ, Inc. Enters into Definitive Agreement to be Acquired by Bansk G...

PetIQ, Inc. Enters into Definitive Agreement to be Acquired by Bansk Group PetIQ Stockholders to Receive $31.00 Per Share in an All-Cash Transaction Valued at Approximately $1.5 Billion EAGLE, Idaho, and NEW YORK, New York, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, and Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, today announced that PetIQ entered into a definitive agreement (the “Agreement”) pursuant to which Bansk...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch